Acadia Healthcare Co Stock (NASDAQ: ACHC)

Acadia Healthcare Co (NASDAQ:ACHC) Stock, Quote.Headers.trade-ideas

Acadia Healthcare Co

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.

Arcadia_Logo copy

Analyst Color

News

Upgrades

Health Care

Price Target

Analyst Ratings

General

ACHC

KeyBanc anticipates healthcare services stocks will thrive in 2025, with growth driven by higher patient volumes and improving Medicare Advantage policies.

Psychiatric Hospital Operator Acadia Healthcare Earns Upgrade Amid Expected Recovery In 2025

The Robinhood Trade

Pre-Market Outlook

Markets

Trading Ideas

HOOD

LULU

SNOW

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Quantum Computing

Mid Cap

Movers

BBAR

LUNR

RGTI

VEON

8 top-performing mid-cap stocks last week: RGTI, VEON, NEXT, GDS, ACHC, LUNR, BBAR, TGS. Did you have them in your portfolio?

Rigetti Computing, VEON And Intuitive Machines Are Among Top Mid-Cap Gainers Last Week (Dec 30-Jan 3): Are The Others In Your Portfolio?

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

RBC Capital analyst Ben Hendrix reiterates Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Outperform and maintains $64 price target.

Reiteration

RBC Capital Reiterates Outperform on Acadia Healthcare Co, Maintains $64 Price Target

KeyBanc Capital Markets writes that Healthcare Services stocks are expected to see significant changes in 2025.
Strong volumes, increased enrollment in health insurance exchanges (HIX) and Medicaid-directed payment programs (DPPs) will likely benefit hospitals.
However, the uncertain policies under Trump may still affect investor confidence.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39803259/uhs-acadia-healthcare-navigate-scrutiny-amid-safety-concern-allegations-at-psychiatric-hospitals-o" rel="noreferrer noopener">UHS, Acadia Healthcare Navigate Scrutiny Amid Safety Concern Allegations At Psychiatric Hospitals, Operating As Nonprofit</a>
Medicare Advantage (MA) managed care organizations (MCOs) are still facing higher costs, but the funding situation for MA could improve in the first half of 2025, offering a clearer path for profit recovery in 2026 and beyond.
As the industry approaches 2025, KeyBanc analyst Matthew Gillmor says he prefers stocks tied to higher patient volumes that are somewhat protected from policy changes.
The analyst expects patient volumes to stay high due to strong HIX enrollment and ongoing post-COVID trends, which will benefit hospitals&#8217; earnings but may limit earnings growth for MCOs.
KeyBanc highlights that volume comparisons will be tough and will monitor proprietary data for trend changes.
Healthcare policy will be a key focus in the first half of 2025, with HIX subsidies and Medicaid DPP being important for hospitals and the 2026 MA rate notice as well as Humana Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) lawsuit being key for MCOs.
KeyBanc expects the policy situation for MA MCOs to improve by April, with UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) being the top choice to benefit from this. Additionally, sentiment around behavioral hospitals, particularly Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), is likely at its lowest.
KeyBanc has upgraded Acadia Healthcare to Overweight from Sector Weight with a price target of $70, citing meaningful higher inflection during 2025 as investors gain visibility into the potential 2026 EBITDA acceleration and valuation returns to historical ranges.
Acadia&#8217;s stock lagged behind the market in 2024 due to <a href="https://www.benzinga.com/news/large-cap/24/09/41067826/federal-investigations-continue-for-psychiatric-hospital-chain-operator-acadia-healthcare-even-aft" target="_blank" rel="noreferrer noopener">external challenges</a> and rising startup expenses, which hurt EBITDA in 2024 and 2025. The analyst believes these issues will improve by 2026, as new beds added in 2024-2025 start to pay off and the increase in startup losses during 2025 slows down or stabilizes.
Price Action: ACHC stock is up 1.45% at $45.50 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42856421/from-earth-to-the-moon-intuitive-machines-and-nokia-launch-4glte-network" target="_blank" rel="noreferrer noopener">Intuitive Machines Finalizes Lunar Lander Installation, Paving The Way For Nokia Network On The Moon</a></li>
</ul>
Courtesy photo

During the last three months, 6 analysts shared their evaluations of Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.67, a high estimate of $75.00, and a low estimate of $43.00. Highlighting a 8.5% decrease, the current average has fallen from the previous average price target of $67.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1736272849_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$66.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Acadia Healthcare Co's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Acadia Healthcare Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Unraveling the Financial Story of Acadia Healthcare Co</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Acadia Healthcare Co's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.7%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching 8.35%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Acadia Healthcare Co's ROE stands out, surpassing industry averages. With an impressive ROE of 2.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Acadia Healthcare Co's ROA excels beyond industry benchmarks, reaching 1.18%. This signifies efficient management of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average. With a ratio of 0.66, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Acadia Healthcare Co Stands With Analysts

TD Cowen analyst Ryan Langston maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Buy and lowers the price target from $70 to $66.

TD Cowen Maintains Buy on Acadia Healthcare Co, Lowers Price Target to $66

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Elizabeth Anderson upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintained the price target of $140. Cardinal Health shares closed at $119.63 on Monday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan analyst Kenneth Worthington upgraded Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Neutral and boosted the price target from $20 to $43. Robinhood shares closed at $42.71 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc analyst Matthew Gillmor upgraded the rating for Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Sector Weight to Overweight and announced a $70 price target. Acadia Healthcare shares closed at $44.85 on Monday. <a href="https://www.benzinga.com/quote/ACHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Aneesha Sherman upgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Market Perform to Outperform. Lululemon shares closed at $395.31 on Monday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Turrin upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Equal-Weight to Overweight and raised the price target from $150 to $200. Snowflake shares closed at $163.08 on Monday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png" alt="" class="wp-image-721866" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34.png 1155w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Keybanc analyst Matthew Gillmor upgrades Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Sector Weight to Overweight and announces $70 price target.

Keybanc Upgrades Acadia Healthcare Co to Overweight, Announces $70 Price Target

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares escalated 23.19% as the quantum computing sector saw increased interest.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) stock surged 17.03%. The company announced that Kyivstar inked an agreement with Starlink to introduce groundbreaking direct-to-cell <a href="https://www.benzinga.com//node/42717832" target="_blank" rel="noreferrer noopener">satellite connectivity in Ukraine</a>.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) stock jumped 16.90% on gains in crude oil and natural gas prices.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock increased 16.05% amid continued interest sparked by reports that the company is evaluating an initial public offering (IPO) for<a href="https://www.benzinga.com//node/42710683" target="_blank" rel="noreferrer noopener"> its data center assets in China</a>.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares rose 14.79% on U.S. healthcare executives&#8217; bullish outlook for 2025.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares were up 13.89% last week. The stock was on the top ten trending list on WallStreetBets.</li>
<li>Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) shares increased 11.81%, joining the ride in Argentina stocks.</li>
<li>Transportadora de Gas del Sur SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGS#NYSE">TGS</a>) stock grew 11.93%, joining the ride in Argentina stocks.</li>
</ol>
Image via Shutterstock

Deutsche Bank analyst Pito Chickering upgrades Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Hold to Buy and raises the price target from $45 to $75.

Deutsche Bank Upgrades Acadia Healthcare Co to Buy, Raises Price Target to $75

In the last three months, 7 analysts have published ratings on Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $72.71, along with a high estimate of $94.00 and a low estimate of $43.00. Observing a downward trend, the current average is 12.09% lower than the prior average price target of $82.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1733857278_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Acadia Healthcare Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Acadia Healthcare Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>A Deep Dive into Acadia Healthcare Co's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Acadia Healthcare Co's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.7%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Acadia Healthcare Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.35%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acadia Healthcare Co's ROE stands out, surpassing industry averages. With an impressive ROE of 2.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Acadia Healthcare Co's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Acadia Healthcare Co Through 7 Analysts

Cantor Fitzgerald analyst Sarah James reiterates Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and maintains $52 price target.

Cantor Fitzgerald Reiterates Neutral on Acadia Healthcare Co, Maintains $52 Price Target

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $76 to $43.

Barclays Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $43

5 analysts have shared their evaluations of Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $82.8, a high estimate of $94.00, and a low estimate of $64.00. Highlighting a 8.2% decrease, the current average has fallen from the previous average price target of $90.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1731960028_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Acadia Healthcare Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Breaking Down Acadia Healthcare Co's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.7% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching 8.35%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Acadia Healthcare Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.28% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Acadia Healthcare Co's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average. With a ratio of 0.66, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 5 Analyst Evaluations For Acadia Healthcare Co

RBC Capital analyst Ben Hendrix maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Outperform and lowers the price target from $94 to $64.

RBC Capital Maintains Outperform on Acadia Healthcare Co, Lowers Price Target to $64

WIIM

Acadia Healthcare shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY24 guidance below estimates.

Earnings

Guidance

Acadia Healthcare Sees 2024 Revenue $3.150B-$3.165B Vs $3.204B Est.; Adj. EPS $3.35-$3.45 Per Share Vs $3.520 Est.

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares moved upwards by 28.8% to $4.2 during Wednesday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares increased by 11.21% to $6.25. The market value of their outstanding shares is at $877.9 million. The company's, Q3 earnings came out today. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock rose 10.79% to $0.9. The market value of their outstanding shares is at $32.8 million. </li>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) stock rose 9.2% to $21.0. The market value of their outstanding shares is at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 7.56% to $2.7. The market value of their outstanding shares is at $9.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 7.5% to $1.29. The company's market cap stands at $91.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares fell 16.8% to $39.0 during Wednesday's after-market session. The company's market cap stands at $4.0 billion. The company's, Q3 earnings came out today. </li>
<li>Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares decreased by 13.22% to $45.2. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock decreased by 12.77% to $0.34. The company's market cap stands at $2.4 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares declined by 7.43% to $1.87. The market value of their outstanding shares is at $7.1 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) stock decreased by 6.69% to $3.35. The company's market cap stands at $107.8 million. </li>
<li>Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) stock fell 6.31% to $3.93. The market value of their outstanding shares is at $162.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIX

ATEC

CMAX

CORT

CTOR

ELDN

ESLA

NVST

TFFP

TNON

VERO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.90 by 1.11 percent. The company reported quarterly sales of $815.63 million which missed the analyst consensus estimate of $819.43 million by 0.46 percent. This is a 8.70 percent increase over sales of $750.33 million the same period last year.

Earnings Beats

Earnings Misses

Acadia Healthcare Co Q3 2024 Adj EPS $0.91 Beats $0.90 Estimate, Sales $815.63M Miss $819.43M Estimate

Acadia Healthcare shares are trading lower following a report indicating the Veterans Department is investigating the company for insurance fraud.

<a href="https://www.nytimes.com/2024/10/18/business/acadia-healthcare-veterans-affairs-investigation.html">https://www.nytimes.com/2024/10/18/business/acadia-healthcare-veterans-affairs-investigation.html</a>
The Veterans Affairs Department is investigating whether Acadia Healthcare, one of the country's largest chains of psychiatric hospitals, is defrauding government health insurance programs by holding patients longer than is medically necessary, according to three people with knowledge of the inquiry.
The investigation, led by the agency's inspector general, comes three weeks after <a href="https://www.nytimes.com/2024/09/27/business/acadia-federal-investigations.html">Acadia told investors</a> that it was facing scrutiny for its admissions practices from several other federal investigators, including prosecutors in Manhattan and a grand jury in Missouri. The company, which relies on government insurance programs like Medicare and Medicaid for much of its revenue, said it was also expecting to receive inquiries from the Securities and Exchange Commission and other agencies.
Acadia told investors that it was "fully cooperating with authorities and, at this time, cannot speculate on whether the outcome of these investigations will have any impact on its business or operations." The company has denied claims that it was improperly holding patients and has said that all decisions about care are made by licensed medical professionals.
The Veterans Affairs Department did not immediately respond to questions about the new investigation.
&nbsp;
<a href="https://www.nytimes.com/2024/09/01/business/acadia-psychiatric-patients-trapped.html">The New York Times reported</a> in September that Acadia was holding patients against their will in ways that appeared to violate state laws. The Times reported that some patients arrived at emergency rooms seeking routine mental health care but then were sent to Acadia facilities and locked in. The company's employees often held patients until their insurance coverage ran out, even when there was no medical justification.
The Times article was based on official complaints, court records and interviews with patients, as well as more than 50 current and former Acadia employees.
Last month, Acadia <a href="https://www.nytimes.com/2024/09/26/health/acadia-doj-settlement-fbi.html">agreed to pay</a> almost $20 million to settle Justice Department claims that the company had defrauded government health insurers by holding patients longer than medically necessary and admitting people who didn't need to be there. Acadia did not acknowledge wrongdoing in that case, which covered conduct from 2014 through 2017.
The fresh round of investigations are focused on recent events. The veterans agency is looking into whether Acadia billed insurance programs for patients who were stable enough to be released and did not need intensive inpatient care, according to two of the people with knowledge of the investigation, who requested anonymity because it has not been made public.
Several former Acadia employees in Georgia and Missouri have also recently been interviewed by agents from the F.B.I. and the inspector general's office of the Health and Human Services Department.

Legal

'Veterans Dept. Investigating Acadia Healthcare For Insurance Fraud; Several Federal Agencies Are Investigating Whether The Large Chain Of Psychiatric Hospitals Held Patients Without Medical Justification' - NY Times

Acadia Healthcare has 'attractive risk-reward' despite negative news: Deutsche Bank

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jazz Pharmaceuticals (JAZZ – Research Report), Acadia Healthcare ...

Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)

Worst performing stocks for tax loss selling – Wolfe

U.S. healthcare spending climbs 7.5% in 2023

U.S. healthcare execs turn more bullish for 2025: Deloitte

KeyBanc upgraded Acadia Healthcare (ACHC) to Overweight from Sector Weight with a $70 price target The stock "could inflect meaningfully higher" du...

Acadia Healthcare upgraded to Overweight from Sector Weight at KeyBanc

In a report released today, Ryan Langston from TD Cowen maintained a Buy rating on Acadia Healthcare (ACHC – Research Report), with a price target ...

TD Cowen Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)

TD Cowen lowered the firm's price target on Acadia Healthcare (ACHC) to $66 from $70 and keeps a Buy rating on the shares. The firm lowered forward...

Acadia Healthcare price target lowered to $66 from $70 at TD Cowen

Acadia upgraded at KeyBanc on EBITDA potential

In a report released today, Ben Hendrix from RBC Capital reiterated a Buy rating on Acadia Healthcare (ACHC – Research Report), with a price target...

RBC Capital Keeps Their Buy Rating on Acadia Healthcare (ACHC)

ACLS

AGCO

ALGM

AMKR

APLS

ATKR

BIIB

BMRN

BRBR

CLVT

CNXC

COLD

DINO

DXCM

ENPH

FIVN

FLNC

GMAB

INTC

IONS

IPGP

JAZZ

LFST

MCHP

MRNA

NEOG

OPCH

PTEN

QDEL

QRVO

REGN

REXR

SEDG

SGRY

STNE

SWKS

SYNA

WOLF

XRAY

Press Releases

ACHC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Acadia Healthcare Company, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ACADIA HEALTHCARE 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Acadia Healthcare Company, Inc. - ACHC

ACHC Deadline: ACHC Investors with Losses in Excess of $100K Have Opportunity to Lead Acadia Healthcare Company, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Healthcare Company Inc. (ACHC)

ACHC CLASS ACTION ALERT: The Acadia Healthcare December 16 Securities Fraud Deadline is Approaching – Contact BFA Law if You Lost Money (NASDAQ:ACHC)

Acadia Healthcare (ACHC) FINAL DEADLINE ALERT: Hagens Berman Encourages ACHC Investors with $200k Losses to Contact the Firm Before Dec. 16, 2024 Deadline in Securities Class Action

DEADLINE ALERT for ACHC, AIXI, and MAPS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Acadia Healthcare

ACHC DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Acadia Healthcare Company, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 16 Deadline in Securities Class Action First Filed by the Firm – ACHC

Acadia Healthcare to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Comments

Acadia Healthcare Co

Acadia Healthcare Co (ACHC) Forecast

Acadia Healthcare Co (NASDAQ:ACHC) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga